Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344682 | 0.84 | MAPT (0.42) | CYP3A4CYP2A6POLBLMNAPKM | |
| SCHEMBL4336312 | 0.84 | ALDH1A1 (0.51) | SLC9A1CYP3A4CYP2A6LMNAALDH1A1 | |
| SCHEMBL4329325 | 0.83 | SLC9A1 (0.36) | SLC9A1LMNAALDH1A1NPSR1KMT2A | |
| SCHEMBL4338180 | 0.82 | CYP2A6 (0.38) | CYP3A4CYP2A6POLBALDH1A1MAPT | |
| SCHEMBL4557720 | 0.82 | CYP2A6 (0.38) | CYP3A4CYP2A6POLBALDH1A1MAPT | |
| SCHEMBL4323303 | 0.82 | KDM4E (0.42) | CYP3A4CYP2A6POLBLMNAPKM | |
| SCHEMBL4338798 | 0.82 | CYP2A6 (0.48) | CYP3A4CYP2A6POLBTP53LMNA | |
| SCHEMBL4329107 | 0.81 | ALDH1A1 (0.45) | CYP3A4CYP2A6POLBLMNAPKM | |
| SCHEMBL4334594 | 0.81 | MAPT (0.46) | SLC9A1CYP3A4CYP2A6POLBTP53 | |
| SCHEMBL4340661 | 0.80 | CYP2A6 (0.42) | SLC9A1CYP3A4CYP2A6POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | SLC9A1 1915/4885NR1D1 924/4885NR1H3 1129/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | SLC9A1 1542/4885NR1D1 900/4885NR1H3 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.